Amaya Skabelund, DO
Pulmonary Disease · Dallas, TXNPI 1801179759
Payments from drug & device makers
Across 228 payments — averaging $71.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Pulmonx Corporation$2K
- AstraZeneca$962
- GSK$931
- Johnson & Johnson$599
- United Therapeutics Corporation$521
- plus $2K from 17 others
What the payments were for
- Travel & lodging$7,70747%
- Food & beverage$6,52440%
- Education$2,07913%
- Gifts$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 38 | $9,737 |
| Pulmonx Corporation | 6 | $1,518 |
| AstraZeneca | 28 | $962 |
| GSK | 69 | $931 |
| Johnson & Johnson(2 entities) | 14 | $599 |
| United Therapeutics Corporation | 9 | $521 |
| Actelion Pharmaceuticals US, Inc. | 6 | $389 |
| Regeneron Healthcare Solutions, Inc. | 7 | $286 |
| Boehringer Ingelheim | 10 | $234 |
| Mylan Specialty L.p. | 8 | $188 |
| Sanofi | 4 | $161 |
| Galvanize Therapeutics, Inc | 1 | $137 |
| Gilead | 3 | $133 |
| Genentech USA, Inc. | 1 | $116 |
| Electromed, Inc. | 6 | $79 |
| Insmed, Inc. | 4 | $68 |
| Inogen, Inc. | 4 | $67 |
| Baxter Healthcare | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $37 |
| Merck | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,023
- ZEPHYR ENDOBRONCHIAL VALVE$1,382
- Monarch Platform$386
- TEZSPIRE$300
- FASENRA$300
- SYMBICORT$300
- UPTRAVI$245
- OPSUMIT$245
- BREZTRI$233
- TYVASO$227
- AIRSUPRA$167
- BEVESPI AEROSPHERE$167
- ALIYA SYSTEM$137
- DUPIXENT$120
- TECENTRIQ$116
- Veklury$100
How this compares
$16,334 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 342 | $265,420 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 327 | $174,542 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 11 | $166,779 |
| Fasenra PenBenralizumab | 26 | $116,975 |
| NucalaMepolizumab | 12 | $44,375 |
| Ambrisentan | 13 | $36,823 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,393 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 57 | $26,848 |
| Advair HfaFluticasone Propion/Salmeterol | 56 | $25,578 |
| Pirfenidone | 20 | $23,255 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $20,829 |
| EliquisApixaban | 23 | $15,379 |
| Mycophenolate Mofetil | 144 | $14,814 |
| Spiriva RespimatTiotropium Bromide | 22 | $13,775 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 350 | $11,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $962 | $296,538417 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $234 | $188,318349 claims |
| Insmed, Inc.Arikayce | $68 | $166,77911 claims |
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta | $931 | $102,445104 claims |
| Johnson & JohnsonXarelto | $599 | $6,63312 claims |
| MerckDulera | $23 | $4,10313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Trushil ShahDallas$1.4M
- Yolanda MagetoDallas$1.4M
- Mark MillardDallas$1.2M
- Chetan NaikDallas$678K
- Craig GlazerDallas$469K
- Yosafe WakwayaDallas$439K
- Sonja BartolomeDallas$423K
- Corey KershawDallas$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.